Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Ontrak CEO Terren Peizer resigned on March 2, a day after US authorities charged him with insider trading, the company said.
Read Full NewsDupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.
Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.
Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.
Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.
Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.
1.
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted
2.
PRO Data Strengthen Case for Dato-DXd in First-Line TNBC
3.
improvements in the treatment of prostate cancer resistant to chemotherapy.
4.
Tumor characteristics found to differ for melanomas in children, teens and young adults
5.
Canadian Group Calls for Earlier Colorectal Cancer Screening
1.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
2.
The Pros and Cons of Steroid Therapy for ITP
3.
The Risk Factors of Venous Thromboembolism and How to Lower Your Chances
4.
Uncovering the Mystery of the Sessile Serrated Adenoma
5.
Understanding Sideroblastic Anemia and its Symptoms
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge